Abstract: The invention concerns a pharmaceutical or cosmetic composition, characterised in that it comprises at least a compound for inhibiting Langerhans' cell migration, said active compound being selected in the group consisting of protein kinase C (PKC) inhibiting compounds, matrix metalloprotease (MMP) inhibiting compounds, and combinations thereof, and at least a pharmaceutically or cosmetically acceptable carrier. Said composition enables to inhibit considerably Langerhans' cell migration induced by the presence or an allergenic agent.

Abstract: Methods of treating a specific cancer or amyloidosis are disclosed. Specific methods encompass the administration of 3-(4-amino-1 oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione alone or in combination with a second active ingredient.

Abstract: A combination kit for the treatment of malaria caused by Plasmodium vivax (P. vivax) having individual doses of an anti-malarial agent, 3-[1-[[4-[(6-methoxy-8-quinolinyl)amino]pentyl]amino]ethylidene]-dihydro-2(3H)-furanone (I) in the form of capsules; individual doses of the anti-malarial agent, chloroquine in the form of tablets; and instruction material for the administration of the two anti-malarial drugs. The combination kit is particularly suited for a 6 days treatment regimen where the treatment is rendered by five tablets containing 500 mg of chloroquine phosphate (equivalent to 300 mg base), three to be taken on day one and one each on days two and three; and five capsules containing 25 mg of 3-[1-[[4-[(6-methoxy-8-quinolinyl)amino]pentyl]amino]ethylidene]-dihydro-2(3H)-furanone (I), one each to be taken on days two to six.

Abstract: The present invention relates to a method for treating pain, reflex sympathetic dystrophy, spasticity, and bipolar disorder using ligands of the ?2? voltage-gated calcium channel, wherein the ligand comprises (2s)-aminophenyl acetic acid and derivatives.